TACSTD2 and cancer: Because govitecan is an active metabolite of irinotecan, the govitecan released from sacituzumab, which attaches to Trop-2 positive cancer cells, may upregulate Trop-2 expression in neighboring cells, thereby enhancing the bystander effect of sacituzumab govitecan.